Objective: To develop an innovative therapy against ischemic stroke (ACS) and complications derived from reperfusion techniques, such as hemorrhagic transformation (HT), through the use of targeted protein degraders. These degraders, mAb-LYTACs, are heterobifunctional molecules composed of a highly specific monoclonal antibody (MAb) against a protein of interest and an internalizing peptide that target said extracellular proteins to lysosomal degradation.
Pursued results: complete the preclinical development of these compounds by evaluating, in vitro and in vivo, their Mechanism of Action (MoA), biodistribution, safety and efficacy.
Beneficiary company, group leader: Aptadegrad, S.L.
Other beneficiaries: AMS Biopharma Laboratory, S.L., Fundación Pública Galega Instituto de Investigación Sanitaria de Santiago de Compostela FIDIS, Diversa Technologies, S.L.
Dates: 15/05/2024 – 15/12/2027
IN856C 2024/08